Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 23304735)

1.

Pushback on Zaltrap's price highlights sensitive end-of-life issue.

Dalzell MD.

Manag Care. 2012 Dec;21(12):40-1. No abstract available.

2.

Colorectal cancer: complexities and challenges in managed care.

Minkoff NB.

J Manag Care Pharm. 2007 Aug;13(6 Suppl C):S27-9.

3.

The development of a value based pricing index for new drugs in metastatic colorectal cancer.

Dranitsaris G, Truter I, Lubbe MS.

Eur J Cancer. 2011 Jun;47(9):1299-304. doi: 10.1016/j.ejca.2011.03.015. Epub 2011 Apr 13.

PMID:
21493060
4.

A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.

Dranitsaris G, Ortega A, Lubbe MS, Truter I.

J Oncol Pharm Pract. 2012 Mar;18(1):57-67. doi: 10.1177/1078155210390724. Epub 2011 Mar 7.

PMID:
21382915
5.

The drug that could have been.

Schultz S.

US News World Rep. 2002 Aug 19;133(7):18, 20-3. No abstract available.

PMID:
12195678
6.

Clinical benefits of stabilisation with second line chemotherapy in patients with metastatic colorectal cancer.

Henry B, Becouarn Y, Aussage P.

Crit Rev Oncol Hematol. 1999 Nov;32(2):145-54. No abstract available.

PMID:
10612014
7.

Biotech firm faces challenges from FDA, falling stock prices.

Reynolds T.

J Natl Cancer Inst. 2002 Mar 6;94(5):326-8. No abstract available.

8.

Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.

Hoskins PJ, Fung-Kee-Fung M, Miller D, Gotlieb W.

J Clin Oncol. 2015 May 10;33(14):1539-42. doi: 10.1200/JCO.2014.58.3690. Epub 2015 Apr 6. No abstract available.

PMID:
25847922
9.

Paying the piper for pharmacoeconomic studies.

Neumann PJ.

Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S23-6. No abstract available.

PMID:
9566464
10.

Expensive cancer therapies: unintended effects.

Delude CM.

J Natl Cancer Inst. 2015 Jan 6;107(1):497. doi: 10.1093/jnci/dju497. Print 2015 Jan. No abstract available.

PMID:
25564602
11.

Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.

Smith JJ, Henderson JA.

J Am Coll Radiol. 2008 Mar;5(3):189-92. doi: 10.1016/j.jacr.2007.09.005.

PMID:
18312966
12.

Cost consequences of the 340B drug discount program.

Conti RM, Bach PB.

JAMA. 2013 May 15;309(19):1995-6. doi: 10.1001/jama.2013.4156. No abstract available.

13.

Larger companies dominate cancer companion diagnostic approvals.

Schmidt C.

Nat Biotechnol. 2011 Nov 8;29(11):955-7. doi: 10.1038/nbt1111-955. No abstract available.

PMID:
22068512
14.

Valuing end-of-life care in the United States: the case of new cancer drugs.

Sorenson C.

Health Econ Policy Law. 2012 Oct;7(4):411-30. doi: 10.1017/S1744133112000217.

PMID:
23079300
15.

Realigning incentives for developing and pricing new anticancer treatments.

Howard DH.

JAMA. 2011 Jun 8;305(22):2347-8. doi: 10.1001/jama.2011.793. No abstract available.

PMID:
21642689
16.

Use and coverage of novel cancer agents in managed care.

Bailes JS.

Semin Oncol. 1994 Dec;21(6 Suppl 14):34-7.

PMID:
7992098
17.

The value of new chemotherapeutic agents for metastatic colorectal cancer.

Howard DH, Kauh J, Lipscomb J.

Arch Intern Med. 2010 Mar 22;170(6):537-42. doi: 10.1001/archinternmed.2010.36. Epub 2010 Mar 16.

PMID:
20233802
18.

Market watch: Upcoming catalysts in Q1 2015.

Uribe A.

Nat Rev Drug Discov. 2015 Jan;14(1):9. doi: 10.1038/nrd4517. Epub 2014 Dec 12. No abstract available.

PMID:
25503330
19.

New drug approved for colorectal cancer.

[No authors listed]

FDA Consum. 2002 Sep-Oct;36(5):2. No abstract available.

20.

Genentech caps cost of cancer drug for some patients.

Pollack A.

N Y Times Web. 2006 Oct 12:C2. No abstract available.

PMID:
17061339
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk